Results 31 to 40 of about 2,468 (182)

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. [PDF]

, 2020
Idarucizumab was approved for the reversal of dabigatran in 2015. We investigated whether postapproval usage patterns of idarucizumab in a real-world setting reflect those observed in the pivotal trials.
Lane, Deirdre A, Reilly, Paul A., Fanikos, John, Reilly, Paul A, França, Lionel Riou, Murwin, Debra, Wowern, Fredrik von, Kermer, Pawel, Butcher, Ken, Gruenenfelder, Fredrik, Lane, Deirdre A., Tartakovsky, Igor   +11 more
core   +1 more source

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures. [PDF]

Transfusion
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Shamiea M, Osnis A, Kashoua A, Avnery O, Itchaki G, Isman S, Tohami T, Jarchowsky-Dolberg O, Ellis M.   +8 more
europepmc   +2 more sources

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

Frontiers in Neurology, 2023
BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ...
Nils Kuklik, Nils Kuklik, Anika Hüsing, Andreas Stang, Andreas Stang, Marcus Brinkmann, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Christian Weimar, Hans-Christoph Diener   +10 more
doaj   +1 more source

No Benefit for Idarucizumab [PDF]

Deutsches Ärzteblatt international, 2016
The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire   +2 more sources

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals

Research and Practice in Thrombosis and Haemostasis, 2021
Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug ...
Jameel Abdulrehman, Sahar Zarabi, Carolyne Elbaz, Kerstin deWit, Yulia Lin, Michelle Sholzberg, Rita Selby   +6 more
doaj   +1 more source

Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients

Future Science OA, 2021
Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.
Eran Kalmanovich, Pascal Battistella, Philippe Rouviere, Bernard Albat, Jean-Marc Frapier, Roland Demaria, Fabien Huet, Audrey Agullo, Marc Mourad, Pascal Colson, Florence Leclercq, Philippe Gaudard, François Roubille   +12 more
doaj   +1 more source

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis [PDF]

, 2017
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
Chak-Wah Kam, Frank W. Sellke, Reilly, Paul A., Young, Laura, Royle, Gordon, Menno V. Huisman, Dubiel, Robert, Charles V. Pollack, Jörg Kreuzer, Bernstein, Richard A., Stephan Glund, Stangier, Joachim, Huisman, Menno V., Peter Verhamme, Glund, Stephan, Sellke, Frank W., Levy, Jerrold H., Weitz, Jeffrey I., Paul A. Reilly, Joanne van Ryn, Steiner, Thorsten, Richard A. Bernstein, Thorsten Steiner, Verhamme, Peter, Jeffrey I. Weitz, Robert Dubiel, Jerrold H. Levy, Gordon Royle, Kamphuisen, Pieter W., Laura Young, Pieter W. Kamphuisen, Pollack, Jr, John W. Eikelboom, Hylek, Elaine M., Kreuzer, Joerg, Wang, Bushi, Elaine M. Hylek, Kam, Chak-Wah, Eikelboom, John W., Joachim Stangier, van Ryn, Joanne, Bushi Wang   +41 more
core   +3 more sources

Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series

Frontiers in Neurology, 2021
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran.
Senta Frol, Dimitrios Sagris, Mišo Šabovič, George Ntaios, Janja Pretnar Oblak   +4 more
doaj   +1 more source

A dabigatran-antidótum, az intravénás idarucizumab első hazai alkalmazása | The first use of iv. idarucizumab for dabigatran reversal in Hungary [PDF]

, 2017
Absztrakt: Az új típusú, direkt orális antikoagulánsok közül jelenleg egyedül a direkt trombingátló dabigatran rendelkezik hatékony antidótummal.
Zoltán Szántó, Barabás, Éva, Gábor Bencsik, Éva Barabás, Szántó, Zoltán, Bencsik, Gábor, Ildikó Bodócs, Herr, György, László Pál, Lajos Driesz, Driesz, Lajos, György Herr, Pál, László, József Borbola, Bodócs, Ildikó, Borbola, József   +15 more
core   +1 more source

PERANAN IDARUCIZUMAB UNTUK MENETRALISIR EFEK ANTIKOAGULAN DABIGATRAN [PDF]

, 2019
Latar Belakang: Dabigatran etexilate (Pradaxa) telah disetujui oleh FDA dan Uni Eropa sebagai antikoagulan untuk mencegah stroke dan emboli sistemik pada pasien dengan atrial fibrilasi non-valvular dan satu atau lebih faktor risiko lain.
Soejitno, Andreas, Putra, Ida Bagus Kusuma   +1 more
core   +1 more source